CAMP4 initiates GLP toxicology studies for CMP-SYNGAP-01; Phase 1/2 target H2 2026

Camp4 Therapeutics Corp

Initiated GLP toxicology studies for CMP-SYNGAP-01, a regulatory RNA-targeting therapeutic for SYNGAP1-related disorders.
Positive preclinical data: restored SYNGAP1 protein in mouse model, increased protein in brain regions of non-human primates.
Planned CTA submission could enable first-in-human Phase 1/2 trial as early as H2 2026.
No FDA-approved disease-modifying therapies exist for SYNGAP1-related disorders; current treatment limited to supportive care.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.